Articles

Information for health professionals about medicines with safety related updates to their Product Information.

Unapproved peptide products are being advertised as delivering fast health results, but they can pose serious health risks to consumers.

New regulations are now in place across Australia to protect public health, by restricting access to nicotine pouches.

TGA has released a new information page relating to the availability of s 9D(1) of the Act to correct information in the ARTG about listed medicines.

The TGA, in partnership with NT Health, Northern Territory Police Force and the Northern Territory Department of Trade, Business and Asian Relations, conducted a targeted multi-agency enforcement operation across three premises in Darwin.

We have issued 5 infringement notices totalling $99,000 to Acacia Pharmacy Pty Ltd for the alleged unlawful importation of unapproved melatonin products, in contravention of the Therapeutic Goods Act 1989.

In March 2026, the Therapeutic Goods Administration (TGA) issued 3 infringement notices totalling $59,400 to Queensland-based company Canngea Pty Ltd.

We've launched a series of interactive e-learning modules designed to help stakeholders understand their regulatory obligations.

Cases of liver injury associated with herbal preparations containing Withania somnifera, commonly known as Ashwagandha, continue to be reported both in Australia and internationally.

We have issued 3 infringement notices totalling $11,880 to a nurse for the alleged unlawful importation of unapproved cosmetic injectables, which is illegal under the Therapeutic Goods Act 1989 (the Act).

From 1 July 2026, some medical devices supplied in Australia must meet Unique Device Identification (UDI) requirements.

We've updated the Listed Medicine Compliance Reports database with the results of compliance reviews covering 13 listed medicines.

Australia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.

We have published new guidance on advertising restrictions for prescription medicines. This is to help individuals and businesses comply with Australia’s regulatory requirements.

Listed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 .

We have issued 5 infringement notices totalling $19,800 to a health practitioner and an individual for the alleged unlawful importation of unapproved cosmetic injectables.

Information for health professionals about medicines with safety related updates to their Product Information.

Six monthly report – supply of unapproved therapeutic goods by a sponsor.

We have expanded our priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply and advertising, posing potential risks to consumer safety.

We have identified reports of FluMist being administered in error to children under 2 years of age.

Medicinal cannabis prescribing in Australia has increased significantly in recent years. However, many patients are unaware that most medicinal cannabis products are unapproved goods. As a prescriber, you play a critical role in ensuring patients are informed, protected and supported when these products are being considered for their clinical situation.

Understanding the difference between an approved and unapproved therapeutic good can help you make informed decisions and have meaningful conversations with your healthcare practitioner, especially when considering treatments like medicinal cannabis.

We have published the outcomes from the targeted consultation, roundtable and stakeholder discussions reviewing certain Authorised Prescriber (AP) scheme requirements for accessing MDMA and psilocybine.

When medicines are in short supply, it can sometimes make patient care more difficult for health practitioners.
We aim to provide clear, timely information to help you access the medicines your patients need during a national medicine shortage. When appropriate, we also make other medicines available so patient care can continue.

ANDEXXA is no longer provisionally approved for use in Australia and has been removed from the Australian Register of Therapeutic Goods (ARTG).